Comparative Pharmacology
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus PRESAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus PRESAMINE.
IMIPRAMINE PAMOATE vs PRESAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Predominantly inhibits serotonin reuptake in the presynaptic neuron, increasing serotonin availability in the synaptic cleft. Also inhibits norepinephrine reuptake to a lesser extent.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
100-300 mg/day orally in divided doses, typically starting at 75 mg/day and titrating upward. Maximum dose 300 mg/day.
None Documented
None Documented
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
21 hours (range 16-28 h) for imipramine; active metabolite desipramine ~24 h; clinically, steady-state reached in 5-7 days.
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Primarily renal (70% as metabolites, <5% unchanged); biliary/fecal (30%).
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant